SEC Form 4 · accession 0001209191-17-065417
REATA PHARMACEUTICALS INC · RETA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Warren Huff
Officer — Chief Executive Officer · Director
Period of report
Dec 12, 2017
Accepted (ET)
Dec 13, 2017 · 4:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358762
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Class B common stockF1 | — | Dec 12, 2017 | M | 10,000 | A | — | — | Class A common stock | 10,000 | 710,806 | D |
| Employee Stock Option (right to buy)F2,F1 | $11.00 | Dec 12, 2017 | M | 10,000 | D | — | May 25, 2026 | Class B common stock | 10,000 | 103,636 | D |
Explanation of responses
- F1The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
- F2The options vest in sixteen equal quarterly installments beginning on August 25, 2016.